First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Patients With Retinitis Pigmentosa (RP)

Trial Profile

First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Patients With Retinitis Pigmentosa (RP)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs ReN 003 (Primary)
  • Indications Retinitis pigmentosa
  • Focus Adverse reactions; First in man
  • Sponsors ReNeuron
  • Most Recent Events

    • 08 Nov 2017 According to a ReNeuron media release, the Data Safety Monitoring Board (DSMB) has given approval for the study to progress into the phase II portion. The company expects read-outs from the phase II portion in the second half of 2018.
    • 23 Apr 2017 Planned End Date changed from 1 Sep 2017 to 1 Apr 2018.
    • 23 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top